Clinical Trial Update: Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluated ropinirole, a non-ergoline dopamine agonist, for hyperprolactinemia and prolactinoma. The study is completed and results we…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperprolactinemia
• Prolactinoma

Drugs mentioned

• Ropinirole (ropinirole)

Snippet

Sponsor: Columbia University | Conditions: Hyperprolactinemia, Prolactinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-07-30